MaxCyte MXCT Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$39.12M+6.4% | -$44.63M-8.7% | -$45.63M-27.7% | -$44.77M-26.4% | -$41.79M-14.3% | ||
| $4.29M-0.2% | $4.34M+0.6% | $4.33M-0.8% | $4.32M-1.3% | $4.3M-0.5% | ||
| $7.32M-44.2% | $9.21M-29.6% | $11.64M-13.9% | $13.06M-5.1% | $13.11M-4.4% | ||
| —— | $3.55M— | —— | —— | —— | ||
| —— | -$287K— | -$531K— | -$613K— | —— | ||
| -$1.24M-46.0% | -$1.15M+14.8% | $3.65M+222% | $1.06M+135% | -$852K+55.2% | ||
| —— | —— | —— | -$1.28M-211% | -$1.72M-165% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $2.03M— | $1.5M— | ||
| —— | —— | -$50K-19.0% | -$62K— | -$9K— | ||
| —— | —— | —— | —— | —— | ||
| $842K+55.9% | $802K+68.8% | $709K+53.5% | $620K+41.6% | $540K+30.1% | ||
| -$1.34M-51.0% | -$1.16M-63.2% | -$1.22M-125% | -$1.09M-136% | -$884K-125% | ||
| -$28.17M+10.5% | -$34.41M-24.6% | -$39.54M-99.8% | -$36.48M-54.3% | -$31.46M-8.8% | ||
| $1.19M-20.9% | $1.77M+7.1% | $1.68M-30.4% | $1.79M-34.5% | $1.5M-49.1% | ||
| —— | —— | —— | —— | —— | ||
| $116.76M-15.1% | $126.29M-16.3% | $130.55M-30.5% | $135.03M-41.2% | $137.46M-44.0% | ||
| $137.16M-20.1% | $155.76M-2.3% | $148.6M-23.7% | $151.6M-35.7% | $171.59M-33.8% | ||
| —— | —— | —— | —— | —— | ||
| $19.06M— | $25.94M— | —— | —— | —— | ||
| $54K-95.8% | $432K-72.9% | $635K-60.4% | $849K-39.9% | $1.28M+13.9% | ||
| $278K-84.0% | $656K-68.1% | $963K-54.9% | $1.18M-39.5% | $1.74M+24.9% | ||
| —— | —— | -$23.99M— | -$22.29M— | —— | ||
| $2.2M-57.2% | $2.65M-57.6% | $3.41M-51.6% | $4.21M-41.0% | $5.14M-30.2% | ||
| —— | —— | —— | —— | —— | ||
| -$1.34M-51.0% | -$1.16M-63.2% | -$1.22M-125% | -$1.09M-136% | -$884K-125% | ||
| $527K+59.2% | $531K+281% | -$1.26M— | $256K— | $331K— | ||
| $808K— | $676K— | $1.46M— | $1.8M— | —— | ||
| —— | —— | —— | —— | —— | ||
| $842K+55.9% | $802K+68.8% | $709K+53.5% | $620K+41.6% | $540K+30.1% | ||
| —— | —— | —— | —— | —— | ||
| $137.16M-20.1% | $155.76M-2.3% | $148.6M-23.7% | $151.6M-35.7% | $171.59M-33.8% | ||
| —— | —— | —— | —— | —— | ||
| -$1.34M-51.0% | -$1.16M-63.2% | -$1.22M-125% | -$1.09M-136% | -$884K-125% | ||
| —— | —— | —— | —— | —— | ||
| -$29.36M+10.9% | -$36.18M-23.6% | -$41.23M-93.6% | -$38.27M-50.3% | -$32.96M-6.5% | ||
| -$29.36M+10.9% | -$36.18M-23.6% | -$41.23M-93.6% | -$38.27M-50.3% | -$32.96M-6.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does MaxCyte generate?
- MaxCyte (MXCT) generated -$28.2M in operating cash flow over the trailing twelve months.
- What is MaxCyte's free cash flow?
- After $1.2M of capital expenditures, MaxCyte's free cash flow was -$29.4M over the trailing twelve months, up 10.9% year over year.
- Where does MaxCyte's cash flow data come from?
- Every line is extracted from MaxCyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
